MedTrace Logo

Proenkephalin A and Kidney Replacement Therapy

NCT04879706 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2023-12-01

No results posted yet for this study

Summary

Acute kidney injury (AKI) is a common problem encountered in the intensive care unit (ICU), estimated to occur in up to 60% of all critically ill patients, depending on the definition. Recent large randomized clinical trials in critical care nephrology have focused on the optimal timing of initiation of acute kidney replacement therapy (KRT). However, less is known about the ideal circumstances in which KRT may be successfully discontinued.

The novel serum-biomarker proenkephalin A 119-159 (penkid) has been found to be strongly negatively correlated with measured GFR. Whether penkid may have a role in initiation and discontinuation of KRT remains unknown.

Conditions

Interventions

OTHER

None planned

No intervention planned

Sponsors & Collaborators

  • University of Giessen

    lead OTHER

Principal Investigators

  • Werner Seeger, MD · University of Giessen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-09
Primary Completion
2023-01-21
Completion
2023-01-21

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04879706 on ClinicalTrials.gov